FIELD: medicine.
SUBSTANCE: invention relates to the medicinal use of miglustat, namely N-butyl-1,5-dideoxy-1,5-imino-D-glucitol in crystalline form I, characterized by the XRPD spectrum shown in FIG. 3, in which the most intense peaks (expressed in 2θ°) must be detected at 9.93, 11.82, 14.46, 15.84, 16.41, 17.76, 17.94, 19.41, 20.01, 20.79, 21.21, 22.14, 22.62, 23.40, 24.75, 26, 04 and 30.27 ± 0.2° at 2θ; and the DSC thermogram shown in FIG. 4, which has an endothermic peak at 129–130 °C, as well as its production method by debenzylation of 2,3,4,6-tetra-O-benzyl-D-glucitol followed by crystallization in C1-C5 alkanol adding C3-C7 ketone with cooling the mixture and extracting solids.
EFFECT: proposed a new crystalline form of valuable compounds and pharmaceutical compositions based on it, effective for the treatment of Gaucher disease.
7 cl, 5 ex, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MIGLUSTAT N-BUTYL-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL | 2019 |
|
RU2743694C1 |
| METHOD FOR PRODUCING (2R,3R,4R,5S)-1-BUTYL-2-(HYDROXYMETHYL)PIPERIDINE-3,4,5-TRIOL | 2020 |
|
RU2762605C1 |
| PROCESS FOR PREPARING DERIVATIVES OF 3,4,5-TRIHYDROXYPIPERIDINE | 0 |
|
SU1050563A3 |
| PROCESS FOR PREPARING DERIVATIVES OF 3,4,5-TRIOXYPIPERIDINE OR THEIR SALTS | 0 |
|
SU1017168A3 |
| COCRYSTALLINE FORM OF C-GLYCOSIDE DERIVATIVE WITH L-PROLIN | 2007 |
|
RU2408595C2 |
| CRYSTALLINE FORMS OF THE DIHYDROPYRIMIDIN DERIVATIVES | 2013 |
|
RU2646599C2 |
| CRYSTALLINE FORMS OF THE TLR7/TLR8 INHIBITOR | 2019 |
|
RU2792005C2 |
| CRYSTALLINE OR AMORPHOUS FORM OF FXR AGONISTS BEING STEROID DERIVATIVES, THEIR PRODUCTION METHOD AND THEIR USE | 2018 |
|
RU2800751C2 |
| C-GLYCOSIDE DERIVATIVES AND THEIR SALTS | 2004 |
|
RU2317288C2 |
| TARTRATE 3-((1R,3R)-1-(2,6-DIFLUORINE-4-((1-(3- FLUOROPROPYL)AZETIDINE-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-b]INDOLE-2-YL)-2,2-DIFLUOROPROPANE-1-OL, ITS SOLID FORMS, METHOD OF ITS PREPARATION AND THEIR APPLICATION | 2019 |
|
RU2809220C2 |
